EFFECTIVENESS OF HORMONAL TREATMENT IN PATIENTS WITH COMBINED ENDOMETRIAL PATHOLOGY AND BENIGN FORMATIONS OF MAMMARY GLANDS

Yu. S. Shapoval
In: Modern medical technology · 2022 · pp. 38–43 · doi:10.34287/mmt.4(55).2022.7 · W4319781151
article OA: diamond CC0
🔓 Open OA copy Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This study evaluated hormonal treatments for endometrial hyperplasia combined with benign breast conditions, finding Danazol to be the most effective regimen for the combined pathology.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-08 · read from full text ⓘ

This prospective study evaluated hormonal treatment regimens for women aged 18–47 with endometrial hyperplasia (HPE), including a main group with HPE plus benign mammary gland diseases and a comparison group with HPE alone. Treatment differed by HPE type: medroxyprogesterone for non-atypical HPE, medroxyprogesterone plus a gonadotropin-releasing hormone (GnRH) analog for atypical HPE, and in combined pathology patients either danazol or medroxyprogesterone combined with “Koberlin” (as reported) to optimize outcomes; the key finding was that the danazol-based regimen was more effective, with estradiol and progesterone levels normalizing by six months in that group. The authors also reported that, in the comparison group, combined medroxyprogesterone plus GnRH analog performed better than medroxyprogesterone alone, based on hormone measurements. A limitation is that the abstract emphasizes biochemical normalization and regimen comparison without detailing relapse endpoints or how randomization/allocation was handled across the groups. Relevance to endometriosis: it connects to the endometrium’s steroid hormone signaling context, citing progesterone/estrogen signaling in endometriosis in the reference list, though its main focus is endometrial hyperplasia with concurrent benign mammary conditions rather than endometriosis or adenomyosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Issues related to the treatment of HPE are still very relevant, which is due to the high frequency of relapses of this disease. Today, in the arsenal of modern medicine, there are various approaches to the treatment of HPE. However, the development of benign neoplasms of the mammary glands against the background of HPE limits the possibilities of conservative treatment. Hormonal therapy remains one of the most common methods of treating HPE. The purpose of the study: to optimize the treatment of patients with various types of hyperplastic processes of the endometrium in combination with benign diseases of the mammary glands. Materials and methods. A prospective study of 90 women aged 18 to 47 was conducted. The main group consisted of patients who were diagnosed with HPE and benign diseases of the mammary glands. The comparison group included patients who were diagnosed with HPE without accompanying pathology of the mammary glands. For the treatment of endometrial hyperplasia without atypia, medroxyprogesterone was used, for the treatment of atypical endometrial hyperplasia, medroxyprogesterone was used in combination with a gonadotropin-releasing hormone analog. For the treatment of patients with combined pathology, the commercial drug Danazol or medroxyprogesterone in combination with Koberlin was used. The results. The implementation of various treatment regimens for patients with HPE and benign breast neoplasms showed that the more effective treatment regimen was the one involving the use of Danazol. In this group of patients, the levels of estradiol and progesterone in the blood plasma normalized already after six months of using the drug. Conclusion. The study of the levels of estrogens, progestins and gonadotropic hormones showed that in the patients of the comparison group, the best treatment scheme is the combined use of medroxyprogesterone and gonadotropin-releasing hormone analogues compared to the monouse of only medroxyprogesterone. In patients with the combined pathology of HPE and mastopathy, the best treatment scheme is the use of Danazol.
Full text 5,651 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Materials

and methods. A prospective study of 90 women aged 18 to 47 was conducted. The main group consisted of patients who were diagnosed with HPE and benign diseases of the mammary glands. The comparison group included patients who were diagnosed with HPE without accompanying pathology of the mammary glands. For the treatment of endometrial hyperplasia without atypia, medroxyprogesterone was used, for the treatment of atypical endometrial hyperplasia, medroxyprogesterone was used in combination with a gonadotropin-releasing hormone analog. For the treatment of patients with combined pathology, the commercial drug Danazol or medroxyprogesterone in combination with Koberlin was used. The results. The implementation of various treatment regimens for patients with HPE and benign breast neoplasms showed that the more effective treatment regimen was the one involving the use of Danazol. In this group of patients, the levels of estradiol and progesterone in the blood plasma normalized already after six months of using the drug. Conclusion. The study of the levels of estrogens, progestins and gonadotropic hormones showed that in the patients of the comparison group, the best treatment scheme is the combined use of medroxyprogesterone and gonadotropin-releasing hormone analogues compared to the monouse of only medroxyprogesterone. In patients with the combined pathology of HPE and mastopathy, the best treatment scheme is the use of Danazol.

References

- Devis-Jauregui L, Eritja N, Davis ML, Matias-Guiu X, Llobet-Navàs D. Autophagy in the physiological endometrium and cancer. Autophagy. 2021;17(5):1077-95. doi: 10.1080/15548627.2020.1752548. - Boychuk AV. Endometrioz: suchasni haydlaynyta praktychnyy dosvid likuvannya. Zdorov’ya Ukrayiny. 2020; № 5: 13-14. - Vovk IB, Zadorozhna TD, Chubey HV, Kondratyuk VK, Parnyts’ka OI, Zakharenko NF. Stan endometriya u zhinok iz henital’nym endometriozom. Zdorov’e zhenschyny. 2010; № 5 (51): 160-162. - Salas A, Vázquez P, Bello AR, Báez D, Almeida TA. Dual agonist-antagonist effect of ulipristal acetate in human endometrium and myometrium. Expert Rev Mol Diagn. 2021;21(8):851-857. doi: 10.1080/14737159.2021.1941878. - Marquardt RM, Kim TH, Shin JH, Jeong JW. Progesterone and estrogen signaling in the endometrium: what goes wrong in endometriosis? Int J Mol Sci. 2019;20(15):3822. doi: 10.3390/ijms20153822. - Gompel A. Progesterone and endometrial cancer. Best Pract Res Clin Obstet Gynaecol. 2020;69:95-107. doi: 10.1016/j.bpobgyn.2020.05.003. - Bruchim I, Sarfstein R, Werner H. The IGF hormonal network in endometrial cancer: functions, regulation, and targeting approaches. Front Endocrinol (Lausanne). 2014;5:76. doi: 10.3389/fendo.2014.00076. - Boguszewski CL, dos Santos CM, Sakamoto KS, Marini LC, de Souza AM, Azevedo M. A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas. Pituitary. 2012;15(1):44-9. doi: 10.1007/s11102-011-0339-7. - Ayele H, Perner M, McKinnon LR, Birse K, Farr Zuend C, Burgener A. An updated review on the effects of depot medroxyprogesterone acetate on the mucosal biology of the female genital tract. Am J Reprod Immunol. 2021;86(3):e13455. doi: 10.1111/aji.13455. - Wang Y, Kuang Y, Chen Q, Cai R. Gonadotropin-releasing hormone antagonist versus progestin for the prevention of premature luteinising hormone surges in poor responders undergoing in vitro fertilisation treatment: study protocol for a randomised controlled trial. Trials. 2018;19(1):455. doi: 10.1186/s13063-018-2850-x. - Demir Karakilic I, Karabacak O, Karabacak N, Guler I, Korucuoglu U. Gonadotropin-releasing hormone analog combined with depot medroxyprogesterone acetate in the management of endometrial hyperplasia a prospective randomized clinical study. J Reprod Med. 2016;61(7-8):361-367. - Al-Badr AA. Danazol. Profiles Drug Subst Excip Relat Methodol. 2022;47:149-326. doi: 10.1016/bs.podrm.2021.10.005. - Chang YT, Teng YN, Lin KI, Wang CCN, Morris-Natschke SL, Lee KH, Hung CC. Danazol mediates collateral sensitivity via STAT3/Myc related pathway in multidrug-resistant cancer cells. Sci Rep. 2019;9(1):11628. doi: 10.1038/s41598-019-48169-2. - Godin R, Marcoux V. Vaginally administered danazol: an overlooked option in the treatment of rectovaginal endometriosis? J Obstet Gynaecol Can. 2015;37(12):1098-103. doi: 10.1016/s1701-2163(16)30075-5. Downloads Published How to Cite Issue Section License The work is provided under the terms of the Public Offer and of Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). This license allows an unlimited number of persons to reproduce and share the Licensed Material in all media and formats. Any use of the Licensed Material shall contain an identification of its Creator(s) and must be for non-commercial purposes only.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (4)

References (11)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK